AbbVie (NYSE:ABBV) reported third-quarter 2026 financial results on October 30, 2026, disclosing worldwide net revenues of $17.404 billion and raising its full-year 2026 adjusted diluted EPS guidance range.

Key Highlights

  • Net revenues of $17.404 billion for Q3 2026, an increase of 10.3 percent on a reported basis and 10.5 percent on an operational basis, according to the filing.
  • GAAP diluted EPS of $2.37 and adjusted diluted EPS of $3.82, both described as increases of over 100.0 percent, each including an unfavorable impact of $0.11 per share related to acquired IPR&D and milestones expense.
  • Immunology portfolio net revenues of $9.165 billion, up 16.3 percent on a reported basis; Skyrizi contributed $5.776 billion and Rinvoq contributed $2.706 billion.
  • Neuroscience portfolio net revenues of $3.389 billion, up 19.4 percent on a reported basis; Botox Therapeutic contributed $1.080 billion and Vraylar contributed $1.068 billion.
  • 2026 adjusted diluted EPS guidance raised to a range of $13.95 to $13.99, up from the prior range of $13.76 to $13.96, including an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q3 2026.
  • Acquisition of Apogee Therapeutics completed, adding assets including zumilokibart and APG273 to AbbVie's immunology pipeline, as disclosed in the filing.
  • 2027 dividend increase of 5.2 percent announced, beginning with the dividend payable in February 2027.

AbbVie's Q3 2026 Portfolio Performance and Guidance Update

According to the filing, AbbVie's worldwide net revenues of $17.404 billion for the third quarter ended September 30, 2026 reflected growth across several key portfolios. The immunology segment led contributions, with global Skyrizi net revenues rising 22.7 percent on a reported basis to $5.776 billion and global Rinvoq net revenues increasing 23.9 percent on a reported basis to $2.706 billion. Global Humira net revenues were $683 million, a decrease of 31.2 percent on a reported basis, or 30.6 percent on an operational basis.

The neuroscience portfolio reported net revenues of $3.389 billion, with Botox Therapeutic at $1.080 billion (up 9.8 percent), Vraylar at $1.068 billion (up 14.3 percent), Ubrelvy at $449 million (up 26.9 percent), Qulipta at $398 million (up 38.2 percent on a reported basis), and Vyalev at $286 million. The oncology portfolio generated $1.696 billion in net revenues, with Venclexta at $803 million (up 10.7 percent), Imbruvica at $522 million (down 26.1 percent), and Elahere at $224 million (up 31.0 percent on a reported basis). The aesthetics portfolio reported $1.176 billion, a decrease of 1.4 percent on a reported basis, with Botox Cosmetic at $669 million and Juvederm at $222 million.

On a GAAP basis, the filing reported an operating margin ratio of 36.0 percent and an adjusted operating margin ratio of 48.7 percent. The GAAP gross margin ratio was 75.4 percent and the adjusted gross margin ratio was 85.1 percent. Net interest expense on a GAAP basis was $700 million. In addition to the completed Apogee Therapeutics acquisition, the filing described FDA approval of Skyrizi for subcutaneous induction in moderately to severely active Crohn's disease and positive topline results from the Phase 3 INTREPID study of lutikizumab in hidradenitis suppurativa.

What Was Disclosed

AbbVie filed its third-quarter 2026 earnings release on October 30, 2026, disclosing revenue, earnings, portfolio segment performance, a raised full-year EPS guidance range, completion of the Apogee Therapeutics acquisition, and a 5.2 percent dividend increase for 2027.